Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$248.13 - $308.36 $1.18 Million - $1.46 Million
-4,750 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$215.51 - $272.51 $4.15 Million - $5.25 Million
-19,250 Reduced 80.21%
4,750 $1.25 Million
Q2 2020

Aug 14, 2020

BUY
$127.44 - $232.72 $3.06 Million - $5.59 Million
24,000 New
24,000 $5.41 Million
Q4 2019

Feb 13, 2020

SELL
$106.59 - $164.21 $598,076 - $921,382
-5,611 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$113.31 - $150.51 $635,782 - $844,511
5,611 New
5,611 $639,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.